What does AOD-9604 actually do? The evidence, honestly

Last updated 2026-07-25

What is AOD-9604, in plain terms?

AOD-9604 is a 16-amino-acid peptide that copies a small piece of human growth hormone, specifically the region from amino acid 176 to 191 at the tail end of the hGH molecule. Researchers call this the "fragment" because it's a fragment, not the whole hormone. The idea behind it goes back to older work on hGH itself. Growth hormone does a lot of things in the body: it drives growth in kids, it affects insulin sensitivity, and separately, it seems to help mobilize and break down fat. Scientists wanted to isolate that last piece, the fat-metabolizing piece, without dragging along the growth-promoting and blood-sugar side effects that make full hGH a controlled, monitored drug. That's the whole premise. AOD-9604 is supposed to be the "fat-burning fragment" of hGH, with the growth and glucose parts engineered out. It was developed under a program run by Australian biotech Metabolic Pharmaceuticals, and a 2004 paper in Current Opinion in Investigational Drugs described it specifically as a metabolic fragment of hGH under investigation for obesity ^[1]. It's worth being clear about what AOD-9604 is not. It's not a growth hormone secretagogue like ipamorelin or CJC-1295, and it's not a growth hormone releasing hormone analog like tesamorelin. It doesn't stimulate your pituitary to make more hGH. It's a direct, synthetic copy of one small section of the hormone itself, given as an exogenous peptide.

How is AOD-9604 supposed to work in the body?

The mechanism, as proposed, is that this fragment binds to fat cells and pushes them toward lipolysis, meaning breakdown of stored triglycerides into free fatty acids the body can use for fuel. In theory, that means less fat storage and more fat mobilization, without touching the IGF-1 pathway that drives tissue growth or the insulin resistance that full-length hGH can cause at higher doses. That's the pitch, and it's a reasonable one on paper. The problem, as with a lot of peptide research, is the gap between "this is a plausible mechanism" and "this produces a measurable, reliable effect in humans that beats placebo." Those are two very different bars, and AOD-9604 has cleared the first one far more convincingly than the second. A 2006 review of obesity drugs in clinical development listed AOD-9604 among candidate compounds being tested for weight-related indications at the time ^[2], which tells you it was taken seriously enough to enter formal drug-development pipelines. It does not tell you the compound worked.

Did AOD-9604 pass human obesity trials?

This is the part that matters most and the part that gets buried too often. AOD-9604 went through clinical trials for obesity, run under Metabolic Pharmaceuticals, and the company itself discontinued the program because the weight-loss results did not separate convincingly from placebo across the trial population. The available peer-reviewed record on AOD-9604 is thin compared to how much it gets talked about online. The 2004 metabolic fragment paper ^[1] and the 2006 obesity-drug pipeline review ^[2] describe it as a compound in development, not as a compound with a positive Phase 3 readout. There is no FDA-approved product built on AOD-9604 in the Drugs@FDA database ^[3], and no drug containing it has cleared an approval pathway in the United States, Australia, or the EU. So the honest summary is: a plausible fragment, a real development program, human trials that ran, and a program that ended without the separation from placebo that a drug needs to get approved. That's a very different story from "clinically proven fat burner," which is how it often gets marketed. If you're the kind of person who wants the mechanism story and the trial outcome side by side, this is the one section to reread before you spend money.

Is there any newer research on AOD-9604?

Not much, and what exists is mostly about detection and safety context rather than new efficacy trials. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, discussing applications and open challenges across a range of peptide compounds used off-label in musculoskeletal contexts ^[4]. A parallel 2026 Sports Medicine paper reviews the safety and efficacy record of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[5]. Neither of those papers reports a new controlled obesity trial for AOD-9604 specifically. They're useful for understanding how AOD-9604 sits inside the broader unapproved-peptide landscape, not for claiming a new efficacy signal exists. If you see a site citing "2026 studies" as proof AOD-9604 works for fat loss, ask exactly which outcome measure improved and by how much. Usually there isn't an answer, because the papers are reviews of the field, not new trial data on this compound. Compare that against tesamorelin, which has an FDA-approved indication (Egrifta) for HIV-associated lipodystrophy backed by published Phase 3 data. If your interest is genuinely "what has the strongest human evidence," that's a real point of separation worth understanding, and it's covered in more depth in our AOD-9604 vs tesamorelin comparison.

Does AOD-9604 show up on doping tests?

No, and this is one of the better-documented facts about the compound. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence the WADA hGH isoform immunoassay, the test anti-doping labs use to detect exogenous growth hormone ^[6]. That means the standard hGH test, which looks at the ratio of different growth hormone isoforms in blood, isn't tripped by this fragment. That is a detection-method finding, not a safety or efficacy finding. It tells you the current isoform test can't catch AOD-9604, not that AOD-9604 is undetectable by every method or that it's fine to use in tested sport. Anti-doping science has moved on since then. A 2014 review in the Journal of Pharmaceutical and Biomedical Analysis covers analytical approaches for detecting emerging therapeutics and non-approved drugs, including peptides like this one, in doping controls ^[7], and a separate 2014 review in Expert Review of Proteomics covers detection strategies for peptidic drugs, candidates, and analogs specifically in sports doping ^[8]. A 2016 paper in the Journal of Separation Science describes a method for screening small peptides under 2 kDa (AOD-9604 is roughly 1.8 kDa) by direct urine injection combined with liquid chromatography and ion mobility mass spectrometry ^[9], which is exactly the kind of newer method built to catch peptides that slip past older immunoassays. If you're an athlete subject to WADA testing, don't read "doesn't trigger the isoform test" as "is allowed." AOD-9604 and related growth hormone fragments fall under WADA's prohibited list regardless of whether a specific assay flags them, and detection methods keep improving.

What does 'gateways to clinical trials' actually tell us about AOD-9604?

Not as much as the name suggests. "Gateways to Clinical Trials" is a recurring feature series that ran in Methods and Findings in Experimental and Clinical Pharmacology in the early-to-mid 2000s, and AOD-9604 shows up in entries from 2003 and 2005 [10, 11, 12]. These are roundup-style summaries of compounds entering or moving through trial pipelines across many indications, not dedicated trial reports with primary outcome data. Seeing AOD-9604 listed in these gateway summaries confirms it was an active clinical candidate during that window. It does not give you a p-value, an effect size, or a placebo comparison. If a source citing these papers implies they show AOD-9604 "working," that's a misread of what a gateway listing is.

How does AOD-9604 compare to other fat-loss peptides with real trial data?

Here's the honest lineup, side by side, based on what's actually been through controlled human trials and regulatory review.

This table isn't exhaustive, but it makes the point. AOD-9604 sits in the "mechanism is interesting, trial record is weak" category. Tesamorelin and the GLP-1 class sit in the "trial record actually holds up" category. If your goal is genuinely maximizing evidence-backed fat loss, the GLP-1 drugs and tesamorelin (for its specific indication) have a much stronger paper trail. See our full AOD-9604 vs tesamorelin comparison for the mechanism and dosing differences in more detail.

Why do people still talk about AOD-9604 for fat loss?

Mostly momentum and marketing, not new data. The compound has a clean story: it's a piece of a hormone your body already makes, engineered to keep the useful part and drop the risky part. That story is easy to repeat and hard to fact-check unless you go looking for the actual trial outcomes, which most retail sellers don't link to. There's also a real gap between research-grade interest and consumer use. AOD-9604 shows up on research-chemical sites sold as "not for human consumption,” which is a legal label, not a safety guarantee, and it tells you nothing about purity or dose accuracy in what you'd actually receive. If you're weighing where research-grade material comes from and how sourcing quality varies, that's worth reading before anything else, and we cover it directly in best place to buy AOD-9604. None of that changes the trial record. A compelling mechanism and a real development history don't substitute for a positive Phase 3 result, and AOD-9604 doesn't have one on the public record.

Is AOD-9604 legal to buy and use in the US?

It's not FDA-approved for any use, and it isn't on either FDA bulks list that allows compounding pharmacies to use a substance in patient prescriptions. The 503A bulk drug substances list, at 21 CFR 216.23, and the 503B list at 21 CFR 216.24 are the specific regulations that say which non-FDA-approved bulk substances a compounding pharmacy may legally use [13, 14]. AOD-9604 is not on either. FDA's own compounding pages lay out how substances get nominated and evaluated for these lists [15, 16]. Compounding law itself runs through 21 U.S.C. 353a, which sets the conditions under which a licensed pharmacist or physician can compound a drug for an identified individual patient ^[10]. Selling AOD-9604 with express or implied health claims ("burns fat,” “targets belly fat”) also runs into FDA's "intended use" regulation at 21 CFR 201.128, which determines when labeling or promotional claims turn a substance into an unapproved new drug in the eyes of the law ^[11]. Practically, that means legitimate US sellers market AOD-9604 as a research chemical, not a therapeutic, and anyone using it outside a research setting is operating outside FDA-approved use and outside the compounding framework.

What are the safety and side-effect concerns with AOD-9604?

There isn't a large, modern safety database for AOD-9604 in humans, because it never reached the post-marketing stage that would generate one. The available published safety signal comes mostly from its early trial program and adjacent peptide-safety literature, not from years of monitored clinical use. The 2026 Sports Medicine review of peptide therapies for musculoskeletal and performance use covers safety data across approved and unapproved peptides used in this space, including compounds like AOD-9604 that circulate outside formal approval ^[5]. That kind of review is useful context, but it underlines the point rather than resolving it: much of what's used off-label lacks the large-scale, long-term safety data that approved drugs have. If you want the fuller rundown of documented and theoretical side effects, injection-site issues, and what's actually been reported versus assumed, that's covered in AOD-9604 side effects, and who should avoid it entirely is in AOD-9604 contraindications. Anyone on other medications, particularly anything affecting glucose or growth pathways, should also look at AOD-9604 drug interactions before combining anything, since the interaction data for this specific fragment is limited and mostly extrapolated from hGH-adjacent compounds rather than studied directly.

So does AOD-9604 actually work for fat loss?

Based on the public record, the honest answer is: not proven. The mechanism is real and reasonably well described (a fragment of hGH's 176-191 region, intended to trigger lipolysis without growth or glucose effects) ^[1], and it did go through a genuine obesity drug-development program ^[2]. But the weight-loss trials didn't produce results that clearly beat placebo, which is why the program was shelved and why no regulator has approved anything containing it. If you're deciding what to do with that information: don't buy AOD-9604 expecting the kind of consistent, published fat-loss effect you'd get from an approved GLP-1 drug or from tesamorelin's approved indication. If you're going to use it anyway, for research purposes, sourcing quality is the single biggest variable in what you actually receive, and it's worth reading how AOD9604Co reviews provider and pharmacy-fulfilled sourcing routes before buying from an unverified research-chemical seller. See best place to buy AOD-9604 for that breakdown.

Frequently asked questions

What is AOD-9604 made from?

AOD-9604 is a synthetic 16-amino-acid peptide copying the 176-191 region at the tail end of human growth hormone. It's manufactured, not extracted from natural hGH, specifically to isolate the fat-metabolism activity researchers associated with that region while dropping the growth and blood-sugar effects of the full hormone ^[1].

Has AOD-9604 been approved by the FDA?

No. There is no FDA-approved drug product containing AOD-9604 in the Drugs@FDA database ^[7], and it doesn't appear on either the 503A or 503B bulk drug substances lists that let compounding pharmacies legally use non-approved substances [13, 14]. It's sold only as a research chemical in the US.

Did AOD-9604 pass its obesity clinical trials?

It went through human obesity trials under Metabolic Pharmaceuticals, but the weight-loss results did not separate convincingly from placebo, and the program was discontinued. The published record, including a 2004 review ^[1] and a 2006 obesity-pipeline review ^[2], describes development activity, not a positive efficacy readout.

Does AOD-9604 show up on a drug test?

A 2013 study found AOD-9604 does not influence the WADA hGH isoform immunoassay, the standard test for exogenous growth hormone ^[5]. That's a specific finding about one assay, not proof it's undetectable overall; newer LC-MS and ion mobility methods target small peptides like this directly ^[9].

Is AOD-9604 the same as HGH?

No. It's a small fragment representing one region of the hGH molecule, not the full hormone. It's designed to keep only the fat-metabolizing activity of hGH while skipping the growth-hormone-receptor and IGF-1 effects that drive tissue growth and affect blood sugar in full-length hGH.

How is AOD-9604 different from tesamorelin?

Tesamorelin is a GHRH analog that stimulates your own pituitary to release more growth hormone, and it has FDA approval (Egrifta) for HIV-associated lipodystrophy backed by published Phase 3 trials. AOD-9604 is a direct synthetic fragment with no FDA approval and an obesity trial record that didn't clearly beat placebo. See AOD-9604 vs tesamorelin for the full comparison.

Why did Metabolic Pharmaceuticals stop developing AOD-9604 for obesity?

The obesity program was discontinued because the weight-loss effects seen in trials did not separate convincingly from placebo across the study population, meaning the drug didn't clear the efficacy bar needed to move toward approval. No large positive Phase 3 result was published to support continued development.

Is it legal to buy AOD-9604 online?

It's sold legally in the US as a research chemical labeled "not for human consumption," which is a legal distinction, not a safety or purity guarantee. It isn't legal to sell with therapeutic claims, since promotional health claims can trigger FDA's intended-use regulation and turn it into an unapproved new drug ^[18].

What are the side effects of AOD-9604?

There's no large modern clinical safety database because AOD-9604 never reached approved, monitored use. Reported and theoretical concerns draw partly from adjacent peptide-safety literature ^[4]. For a full rundown of documented and theoretical effects, see AOD-9604 side effects.

Can AOD-9604 be compounded by a pharmacy in the US?

No. Compounding under 21 U.S.C. 353a requires the substance to meet specific bulk drug conditions, and AOD-9604 isn't on FDA's 503A list (21 CFR 216.23) or 503B list (21 CFR 216.24) [13, 14, 17]. A pharmacy legally compounding patient prescriptions can't use it.

Does newer 2026 research prove AOD-9604 works?

No. Two 2026 papers, one in JAAOS Global Research & Reviews on therapeutic peptides in orthopaedics ^[3] and one in Sports Medicine on peptide safety and efficacy ^[4], discuss AOD-9604 within broader reviews of the peptide field. Neither reports a new controlled obesity trial or a positive efficacy result for the compound specifically.

What's a better evidence-backed option than AOD-9604 for fat loss?

For an approved indication with published Phase 3 data, tesamorelin (Egrifta) is approved for HIV-associated visceral fat reduction. For general weight loss, GLP-1/GIP receptor agonists like semaglutide and tirzepatide have large positive Phase 3 programs and full FDA approval, unlike AOD-9604's discontinued and unproven trial record.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604 as a metabolic fragment of hGH under investigation, specific to the compound's mechanism and development.
2. PubMed, Current Opinion in Investigational Drugs (2006): Lists AOD-9604 among obesity drugs in clinical development at the time of the 2006 review.
3. PubMed, JAAOS Global Research & Reviews (2026): Reviews therapeutic peptides in orthopaedics, including applications and challenges relevant to compounds like AOD-9604.
4. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
5. PubMed, Drug Testing and Analysis (2013): Found that AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect exogenous growth hormone.
6. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs including peptides in doping controls.
7. FDA, Drugs@FDA database: Confirms there is no FDA-approved drug product containing AOD-9604 listed in the database.
8. PubMed, Expert Review of Proteomics (2014): Reviews detection strategies for peptidic drugs, candidates, and analogs in sports doping.
9. PubMed, Journal of Separation Science (2016): Describes a direct urine injection LC/ion mobility mass spectrometry method for screening peptides under 2 kDa, relevant to AOD-9604's size.
10. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Gateways to Clinical Trials entry listing AOD-9604 among compounds active in trial pipelines in 2003.
11. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Second 2003 Gateways to Clinical Trials entry referencing AOD-9604's clinical pipeline status.
12. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): 2005 Gateways to Clinical Trials entry referencing AOD-9604 in ongoing pipeline listings.
13. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substances list a compounding pharmacy may use under 503A; AOD-9604 is not on it.
14. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances list for 503B outsourcing facilities; AOD-9604 is not on it.
15. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the FDA process for evaluating and listing bulk drug substances eligible for 503A compounding.
16. FDA, Bulk Drug Substances Nominated for Use in Compounding: Current FDA list of nominated bulk drug substances under review for compounding eligibility.
17. Cornell Law/LII, 21 U.S.C. 353a: Sets the statutory conditions under which a pharmacist or physician may compound a drug for an identified patient.
18. eCFR, 21 CFR 201.128: Defines how labeling and promotional claims establish a substance's 'intended use' as an unapproved new drug.